keyword
MENU ▼
Read by QxMD icon Read
search

topical cyclosporin

keyword
https://www.readbyqxmd.com/read/28439923/immunosuppressive-drugs-in-whole-blood-validation-of-a-commercially-available-lc-ms-ms-kit-and-comparison-with-immunochemical-assays
#1
Elisa Polledri, Rosa Mercadante, Chiara Ferris Fusarin, Rita Maiavacca, Silvia Fustinoni
RATIONALE: In the determination of immunosuppressive drugs cyclosporine A (CSA), tacrolimus (TARO), sirolimus (SIRO), and everolimus (EVE) in whole blood there is an open debate about which is the best assay between immunochemistry and liquid chromatography-tandem mass spectrometry (LC-MS/MS). This work is aimed to explore this topic, focusing on the use of updated assays and the analysis of a large number of samples. METHOD: A certified in vitro diagnostic kit coupled with a medical device LC-MS/MS was validated and applied to the analysis of 1192 blood samples of patients treated with immunosuppressive drugs...
April 24, 2017: Rapid Communications in Mass Spectrometry: RCM
https://www.readbyqxmd.com/read/28435476/successful-treatment-of-bullous-lichen-planus-with-acitretin-monotherapy-review-of-treatment-options-for-bullous-lichen-planus-and-case-report
#2
Efstathios Rallis, Angeliki Liakopoulou, Constantinos Christodoulopoulos, Alexandros Katoulis
BACKGROUND: Bullous lichen planus (BLP) is a rare variant of lichen planus, characterized by the development of vesicular and bullous lesions, of skin, nails, hair and/or mucosa. MAIN OBSERVATIONS: We present a case of 63-year-old woman with BLP, unresponsive to previous therapies with topical corticosteroids, topical calcipotriol, antihistamines and oral cyclosporine (4 mg/kg/day for 4 months). She was already receiving treatment for arterial hypertension, hyperlipidemia, atrial fibrillation and uncontrolled diabetes mellitus...
December 31, 2016: Journal of Dermatological Case Reports
https://www.readbyqxmd.com/read/28405165/enhancement-of-physicochemical-properties-of-nanocolloidal-carrier-loaded-with-cyclosporine-for-topical-treatment-of-psoriasis-in-vitro-diffusion-and-in-vivo-hydrating-action
#3
Siti Hajar Musa, Mahiran Basri, Hamid Reza Fard Masoumi, Norashikin Shamsudin, Norazlinaliza Salim
Psoriasis is a chronic autoimmune disease that cannot be cured. It can however be controlled by various forms of treatment, including topical, systemic agents, and phototherapy. Topical treatment is the first-line treatment and favored by most physicians, as this form of therapy has more patient compliance. Introducing a nanoemulsion for transporting cyclosporine as an anti-inflammatory drug to an itchy site of skin disease would enhance the effectiveness of topical treatment for psoriasis. The addition of nutmeg and virgin coconut-oil mixture, with their unique properties, could improve cyclosporine loading and solubility...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28382768/low-dose-cyclosporine-a-in-the-treatment-of-severe-atopic-dermatitis-complicated-by-chronic-hepatitis-c-virus-infection
#4
Maria Gnarra, Clara De Simone, Matteo Garcovich, Simone Garcovich
Atopic dermatitis (AD) is the most frequent chronic inflammatory skin disorder in children and is usually accompanied by genetic and environmental factors. Effective management and treatment of AD is challenging and often requires systemic immunosuppressive therapy when refractory to topical treatments. We report a rare association between chronic hepatitis C virus (HCV) and severe AD, management of which required systemic cyclosporine because of its favorable effects on inflammatory and viral-related clinical outcomes...
April 6, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28378336/review-of-treatment-for-alopecia-totalis-and-alopecia-universalis
#5
REVIEW
Sama Kassira, Dorota Z Korta, Lance W Chapman, Francis Dann
Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. This review focuses on the evidence for current treatment options for AT and AU. The PubMed database was searched from January 1, 2000, to September 1, 2016, for clinical trials, retrospective studies, and case reports of treatments for AT and AU...
April 5, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28331873/rapid-corneal-thinning-and-perforated-ulcerative-keratitis-in-a-patient-with-relapsing-polychondritis
#6
Tracy Hiu Ting Lai, Nikki Far, Alvin Lerrmann Young, Vishal Jhanji
BACKGROUND: To report rapid corneal thinning and perforation in a case with relapsing polychondritis. CASE PRESENTATION: A 43 year-old male diagnosed with relapsing polychondritis suffered from bilateral scleritis, bilateral swelling of pinna, saddle nose and tracheal stenosis. The patient presented with right eye pain and redness for one month. Slit lamp examination of the right eye showed 80% peripheral corneal thinning between 3 and 7 o'clock. The best-corrected visual acuity (BCVA) was 1...
2017: Eye and Vision (London, England)
https://www.readbyqxmd.com/read/28318723/pan-european-survey-of-the-topical-ocular-use-of-cyclosporine-a
#7
A Labbé, C Baudouin, D Ismail, M Amrane, J-S Garrigue, A Leonardi, F C Figueiredo, G Van Setten, M Labetoulle
OBJECTIVE: To assess medical practices surrounding the use of topical ocular cyclosporine A across European Union nations. METHODS: Key stakeholders (ophthalmologists, hospital pharmacists, regulatory health authorities) from European Union member states were interviewed by telephone using a semi-structured, open-ended questionnaire. Ophthalmologists responded to questions about practice patterns of cyclosporine A use (prescription frequency, indication, dosage), pharmacists about cyclosporine A formulations (composition, manufacturing process, quality control, distribution), and the regulatory authorities about market authorization and pharmacovigilance for various cyclosporine A products...
March 16, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28300860/annular-elastolytic-giant-cell-granuloma-successfully-treated-with-adalimumab-subsequently-complicated-by-drug-induced-lupus
#8
Adele Haimovic, Hideko Kamino, David E Cohen
We report a 51-year-old female with a 3-year history of recalcitrant annular elastolytic giant cell granuloma (AEGCG) who was effectively treated with the anti-tumor necrosis factor (TNF)-alpha antibody, adalimumab. Her disease was refractory to topical glucocorticoids, intralesional glucocorticoids, narrow-band ultraviolet light (UV)-B phototherapy and cyclosporine. During her treatment with adalimumab she developed a positive anti-nuclear-antibody and double-stranded-DNA antibody and her treatment was terminated...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28299439/vitamin-b12-deficiency-evaluation-and-treatment-in-severe-dry-eye-disease-with-neuropathic-ocular-pain
#9
Serkan Ozen, Murat Atabey Ozer, Mehmet Orçun Akdemir
PURPOSE: This study aims to understand the effect of vitamin B12 deficiency on neuropathic ocular pain (NOP) and symptoms in patients with dry eye disease (DED). METHODS: Patients with severe DED (without receiving topical artificial tears treatment) and ocular pain were enrolled (n = 90). Patients with severe DED and vitamin B12 deficiency (group 1, n = 45) received parenteral vitamin B12 supplement + topical treatment (artificial tears treatment + cyclosporine), and patients with severe DED and normal serum vitamin B12 level (group 2, n = 45) received only topical treatment (artificial tears treatment + cyclosporine)...
March 15, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28251308/-bilateral-ciliary-body-oedema-under-treatment-with-ciclosporine
#10
R Braun, E Holler, D Wolff, H Helbig, C Blecha, T Dietrich-Ntoukas
We present the case of a 27-year-old female patient who developed bilateral ciliary body edema with secondary glaucoma and myopic shift during systemic treatment with cyclosporine for aplastic anemia. After application of topical atropine and prednisolone acetate and conversion from cyclosporine to tacrolimus, the ophthalmologic symptoms resolved completely. Since an infectious etiology was not evident, we hypothesize that ciliary body edema was caused by impairment of microvascular integrity by cyclosporine...
March 1, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28250773/meretoja-s-syndrome-lattice-corneal-dystrophy-gelsolin-type
#11
I Casal, S Monteiro, C Abreu, M Neves, L Oliveira, M Beirão
Lattice corneal dystrophy gelsolin type was first described in 1969 by Jouko Meretoja, a Finnish ophthalmologist. It is caused by an autosomal dominant mutation in gelsolin gene resulting in unstable protein fragments and amyloid deposition in various organs. The age of onset is usually after the third decade of life and typical diagnostic triad includes progressive bilateral facial paralysis, loose skin, and lattice corneal dystrophy. We report a case of a 53-year-old female patient referred to our Department of Ophthalmology by severe dry eye and incomplete eyelid closure...
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/28250361/a-patient-with-cystic-granuloma-trichophyticum-who-required-surgical-resection
#12
Takehiko Kaneko, Michiyo Kaneko
A 62-year-old male with numerous subcutaneous nodules in the lower extremities was referred to The University of Tokyo Hospital. The patient suffered from systemic lupus erythematosus (SLE), diabetes mellitus, and persisting hepatic dysfunction, and had been treated for SLE with oral prednisolone 20 mg/day and oral cyclosporine 3 mg/kg/day. The culture of scales collected from the patient's skin surface on Sabouraud's dextrose agar medium showed features of Trichophyton rubrum. Topically applied bifonazole cream was effective for tinea corporis, but oral griseofulvin 500 mg/day was discontinued after 2-month administration because of deteriorated liver function...
2017: Medical Mycology Journal
https://www.readbyqxmd.com/read/28216719/diagnosis-and-management-of-chronic-pruritus-an-expert-consensus-review
#13
REVIEW
Murlidhar Rajagopalan, Abir Saraswat, Kiran Godse, D S Krupa Shankar, Sanjiv Kandhari, Shrutakirthi D Shenoi, Sushil Tahiliani, V Vijay Zawar
The aim of this study is to formulate the best clinical practice in the diagnosis and management of chronic pruritus (CP). We searched PubMed, EMBASE, Scopus, Web of Science, and the WHO's regional databases, for studies on "Diagnosis and management of chronic pruritus" from January 1, 2014, to July 31, 2015. We included programmatic reports and hand-searched references of published reviews and articles. Two independent reviewers screened articles and extracted data. We screened 87 of 95 studies that contained qualitative data...
January 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28176301/phenotypic-analysis-of-circulating-t-cell-subset-and-its-association-with-burden-of-skin-disease-in-patients-with-chronic-actinic-dermatitis-a-hematologic-and-clinicopathologic-study-of-20-subjects
#14
Toshihisa Hamada, Yumi Aoyama, Yoshinori Shirafuji, Keiji Iwatsuki
BACKGROUND: Chronic actinic dermatitis (CAD) is a recurrent photosensitive dermatitis that occurs predominantly on sun-exposed areas with unknown etiology. In severe cases, it may present with erythroderma, which is clinicopathologically analogous to cutaneous T-cell lymphoma. Typically, inflammatory infiltrates in the skin lesions are mainly CD8(+) reactive T cells. However, hematologic characteristics of CAD have not been fully elucidated. METHODS: Twenty patients with CAD ranging in age from 45 to 86 years (median, 64), including 17 males and three females (M/F ratio, 5...
February 7, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28163544/lifitegrast-a-novel-drug-for-treatment-of-dry-eye-disease
#15
Afroz Abidi, Pooja Shukla, Ali Ahmad
Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, especially in the elderly age group. The mainstay of therapy includes artificial tears, punctual plugs, topical anti-inflammatory agents, and corticosteroids. In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it causes burning sensation in the eye. Hence, progress in new research for a better therapeutic option led to the discovery of lymphocyte function-associated antigen intercellular adhesion molecule 1 antagonist, lifitegrast...
October 2016: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/28157225/corneal-confocal-scanning-laser-microscopy-in-patients-with-dry-eye-disease-treated-with-topical-cyclosporine
#16
B Iaccheri, G Torroni, C Cagini, T Fiore, A Cerquaglia, M Lupidi, S Cillino, H S Dua
PurposeTo investigate the effect of cyclosporine on corneal ultrastructure and on major signs and symptoms of patients with dry eye disease.Patients and methodsIn this prospective cohort study, patients with dry eye disease were treated with a drop of cyclosporine 0.05% twice daily. Clinical evaluation was carried out at baseline and at months 1, 3, and 6. All patients completed the Ocular Surface Disease Index (OSDI) questionnaire, and tear film break-up time (BUT), fluorescein and lissamine green staining, and Schirmer test were carried out...
February 3, 2017: Eye
https://www.readbyqxmd.com/read/28157224/comparison-of-clinical-outcome-with-different-treatment-regimens-in-acute-adenoviral-keratoconjunctivitis
#17
L Asena, E Şıngar Özdemir, A Burcu, E Ercan, M Çolak, D D Altınörs
PurposeTo compare the clinical outcome with different treatment regimens in Acute Adenoviral Keratoconjunctivitis (AAK).MethodsThe records of 110 patients diagnosed as AAK in two tertiary eye care centers were evaluated retrospectively. The treatment regimen, follow-up duration, time until improvement of the symptoms, visual acuity, clinical findings, Schirmer's test and the Ocular Surface Disease Index (OSDI) score at the first day, first week and third week were recorded. The Kruskal-Wallis Test and Chi-square test were used for comparison of quantitative and categorical variables, respectively...
February 3, 2017: Eye
https://www.readbyqxmd.com/read/28146363/keratitis-in-dry-eye-disease-and-topical-ciclosporin-a
#18
Andrea Leonardi, Bruno Flamion, Christophe Baudouin
Tear film alterations in dry eye disease (DED) include reduced tear volume and an increase in inflammatory cytokines. Instability and reduced tear production initiate a vicious cycle where hyperosmolarity, ocular inflammation, and apoptosis may induce damage of the ocular surface including keratitis. Topical cyclosporine (CsA) has been used for the treatment of moderate-to-severe DED; however, previous studies failed to demonstrate its benefits by the European Agency standards. A new formulation of CsA 0.1% has been recently approved in the EU to treat severe keratitis in DED patients...
February 1, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28140549/treatment-options-for-pyoderma-gangrenosum
#19
REVIEW
Sven R Quist, Luise Kraas
Pyoderma gangrenosum (PG) is an orphan disease. While research on such disorders is based on only few randomized multicenter as well as retrospective studies, most of the data comes from case series of small patient groups. Apart from topical and intralesional therapeutic options for early stages and mild disease courses, treatment predominantly involves systemic therapeutic agents. Besides systemic corticosteroids and cyclosporine A (CsA), options also include intravenous immunoglobulins (IVIG) and biologics such as the TNFα inhibitors infliximab, adalimumab, and etanercept; the interleukin (IL) 12/23 antibody ustekinumab; the IL-1 receptor antagonist anakinra; and the IL-1β antibody canakinumab...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28120172/vernal-shield-ulcers-treated-with-frequently-installed-topical-cyclosporine-0-05-eyedrops
#20
Tim Westland, Eliza K Patryn, Carla P Nieuwendaal, Ivanka J E van der Meulen, Maarten P Mourits, Ruth Lapid-Gortzak
PURPOSE: To report on the beneficial results of an intense regimen of 0.05% cyclosporine eye drops, eight times a day in patients with therapy resistant vernal shield ulcers. METHODS: Case cohort of four eyes of three male children with vernal keratoconjunctivitis complicated by shield ulcers, who were treated with frequent cyclosporine 0.05% eye drops and observed for up to 5 years. RESULTS: Quick resolution of the shield ulcers and complete re-epithelialization within 14-25 days was observed after adding intensive treatment with cyclosporine 0...
January 24, 2017: International Ophthalmology
keyword
keyword
36427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"